# Cavion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cavion

- Industry: Pharmaceuticals
- Headquarters: Charlottesville, US
- Website: www.cavionpharma.com
- Total disclosed funding: $26M
- Latest round: Series A (Jan 6, 2017)
- Investors on record: 3

## About

Cavion, Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions for neurological and oncological disorders, targeting unmet medical needs through proprietary drug candidates.Founded in 2014 in Charlottesville, US, Cavion, Inc. specializes in creating therapies for neurological and cancer-related conditions. The company was acquired by Jazz Pharmaceuticals, Inc. in August 2019 for USD 52.5 mn, with a potential additional payment of USD 260 mn based on performance milestones. The company has executed a total of 4 deals since its inception, reflecting its active engagement in the healthcare sector under the leadership of Andrew Krouse, who serves as both founder and CEO.Cavion Pharma specializes in developing innovative therapeutic solutions aimed at addressing unmet medical needs in neurology and oncology. The company’s core product offerings include proprietary drug candidates that target specific pathways involved in neuronal and cancer cell dysfunction. These therapeutics are designed to improve patient outcomes through mechanisms that modulate cellular signaling and promote neuroprotection or inhibit tumor growth. Cavion Pharma primarily serves a diverse client base, including hospitals, specialty pharmacies, and healthcare providers, facilitating access to their treatment options for patients dealing with chronic neurological conditions and various cancer types. The company's products are strategically marketed in North America and select European countries, focusing on regions where there is a significant demand for advanced therapeutic interventions.Cavion Pharma engages in a business model characterized by partnerships with healthcare institutions and pharmaceutical distributors to maximize the reach of its products. Revenue generation occurs through direct sales of their flagship drug candidates to healthcare providers and institutions, as well as through potential licensing agreements with larger pharmaceutical companies seeking to leverage Cavion's proprietary technologies. Transactions typically involve negotiated pricing structures tailored to the needs of hospitals and clinics, reflecting the value of the therapies in improving patient care. The company maintains a focus on building strategic collaborations, which enhances market penetration and allows for sustainable growth in revenue streams associated with their innovative therapeutic offerings.Cavion's strategy includes the development of new drug candidates aimed at enhancing treatment options in neurology and oncology, with several projects in the pipeline for the upcoming years. The company plans to expand its market presence into additional European countries and parts of Asia by 2025, targeting regions that require advanced therapeutic solutions. The recent acquisition by Jazz Pharmaceuticals, Inc. will support these initiatives, providing necessary resources and expertise to accelerate product development and market expansion.

## Funding rounds

- Series A, Jan 6, 2017, $26M — Novartis Venture Fund, Lilly Ventures, Enso Ventures

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Enso Ventures (https://capitalatlas.ai/funds/enso-ventures) — Series A